Press Releases

Press Releases

Nov 15, 2023
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
Nov 09, 2023
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Nov 07, 2023
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
Nov 06, 2023
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Oct 13, 2023
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
Oct 03, 2023
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 19, 2023
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 06, 2023
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 09, 2023
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Jun 08, 2023
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Displaying 1 - 10 of 21
Media & IR Contact
Investor Contact

Robin Garner
Investor Relations
Contact Us

Media Contact

David Rosen
Argot Partners
[email protected]

Helpful Tools